MJ Business Attorneys

JUNE 29, 2018

On Monday, the U.S. Food and Drug Administration (FDA) approved Epidiolex, a drug containing Cannabidiol (CBD). CBD is one of the 80 active chemicals found in the marijuana plant, but unlike the more commonly known cannabinoid chemical Tetrahydrocannabinol (THC), CBD does not produce a “high” Justin Gover, chief executive officer of GW Pharmaceuticals, the UK-based biopharmaceutical company that makes Epidiolex, stated the FDA assessed Epidiolex as having a low to negative potential

DEA 113

DEA CBD Pharmaceutical Research and Development 113

MedicalJane

JUNE 29, 2018

At the time of this article’s publishing, thirty states and the District of Columbia have enacted legislation permitting use of medical cannabis. Of those, nine states and DC have went a step further and legalized marijuana for all adults 21 and over. Although this is exciting for many advocates of the plant, many patients that are suffering from ailing health conditions are left wondering what this means for them, and how exactly all of these changes will impact their healthcare options.

Patients 83

Patients Legalization Conditions Treatment 83

Connor & Connor PLLC

JUNE 29, 2018

The City Council of Las Vegas has taken small steps to join a handful of other cities across the western United States to license and regulate consumption of marijuana and marijuana products outside of private residences. On June 27th, 2018 the City Council hosted a Social Use Workshop to discuss drafted changes to the City Municipal Code. While there is a long way to go before social use venues come to fruition, the proposed changes are good news for the Las Vegas marijuana community.

Consumption 53

Consumption Marijuana Safety Business 53

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Prior to this week, the U.S. Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. None of the approved drugs contain, or are derived from, the whole cannabis plant.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Speaker: Jonathan Bench, International Cannabis and Securities Business Attorney at Harris Bricken

The U.S. cannabis industry is still in its infancy, even though states began engaging with legalization in one form or another in the late 1990s. Today, many opportunities exist for individuals and businesses that want to engage in the industry. Some want to directly own licensed businesses, while others prefer to keep the industry at an arm’s length and merely profit from it.

Cannabis

Meadow

JUNE 29, 2018

[link] [link] Before the interview with Lori, we sent out a survey to licensed operators asking them how CA legalization was going so far, and what questions and comments they have for the BCC. The questions we asked were compiled based off your feedback. We’d like to extend a big thank you to everyone who participated and sent in responses. We are very appreciative of the group effort; your expertise and thoughtfulness is evident in the quality and breadth of the questions.

Supply Chain 40

Supply Chain Wellness and Beauty Retail Cultivation 40